Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS7927614 B2
Publication typeGrant
Application numberUS 11/452,642
Publication dateApr 19, 2011
Filing dateJun 14, 2006
Priority dateFeb 3, 2006
Fee statusPaid
Also published asCA2641420A1, CA2641420C, EP1993569A1, EP1993569A4, EP1993569B1, US20070184017, WO2007089267A1
Publication number11452642, 452642, US 7927614 B2, US 7927614B2, US-B2-7927614, US7927614 B2, US7927614B2
InventorsJoseph R. Faryniarz, Jose E. Ramirez
Original AssigneeJr Chem, Llc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Anti-aging treatment using copper and zinc compositions
US 7927614 B2
Abstract
Composition and methods for alleviating or eliminating age related skin conditions by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate active ingredient.
Images(6)
Previous page
Next page
Claims(23)
1. A method comprising topically applying to a user's skin a composition comprising a copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule.
2. A method as in claim 1 wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule comprises copper-zinc citrate, copper-zinc oxalate, copper-zinc tartarate, copper-zinc malate, copper-zinc succinate, copper-zinc malonate, copper-zinc maleate, copper-zinc aspartate, copper-zinc glutamate, copper-zinc glutarate, copper-zinc fumarate, copper-zinc glucarate, copper-zinc polyacrylic acid, copper-zinc adipate, copper-zinc pimelate, copper-zinc suberate, copper-zinc azelate, copper-zinc sebacate, copper-zinc dodecanoate, or combinations thereof.
3. A method as in claim 1 wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is a copper-zinc malonate.
4. A method as in claim 3 wherein the copper-zinc malonate comprises about 16.5% copper and about 12.4% zinc.
5. The method of claim 1 wherein the molar ratio of copper to zinc in the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is from about 1:1 to about 3:1.
6. The method of claim 1 wherein the molar ratio of copper to zinc in the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is from about 1:1 to about 2:1.
7. The method of claim 1 wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is present in an amount from about 0.001 to about 5% by weight of the composition.
8. The method of claim 1 wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is present in an amount from about 0.05 to about 1% by weight of the composition.
9. The method of claim 1 wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is present in an amount from about 0.1 to about 0.5% by weight of the composition.
10. A method as in claim 1 wherein the composition is a solution, emulsion, microemulsion, suspension, cream, lotion, gel, powder, solid composition, or combinations thereof.
11. The method according to claim 1, wherein the composition comprises a dermatologically acceptable carrier or diluent.
12. A method for forming collagen, elastic fibers, elastin, or tropoelastin in the skin of a patient comprising contacting an area of the skin in need thereof with an effective amount of a composition wherein the composition comprises one or more copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule.
13. The method according to claim 12, wherein the composition comprises a dermatologically acceptable carrier or diluent.
14. The method according to claim 12, wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is selected from the group consisting of copper-zinc citrate, copper-zinc oxalate, copper-zinc tartarate, copper-zinc malate, copper-zinc succinate, copper-zinc malonate, copper-zinc maleate, copper-zinc aspartate, copper-zinc glutamate, copper-zinc glutarate, copper-zinc fumarate, copper-zinc glucarate, copper-zinc polyacrylic acid, copper-zinc adipate, copper-zinc pimelate, copper-zinc suberate, copper-zinc azelate, copper-zinc sebacate, copper-zinc dodecanoate, and combinations thereof.
15. The method according to claim 12, wherein the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule is a copper-zinc malonate.
16. The method according to claim 15, wherein the copper-zinc malonate comprises about 16.5% copper and about 12.4% zinc.
17. The method according to claim 12, comprising from about 0.001 to about 5 percent by weight of the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule.
18. The method according to claim 12, comprising from about 0.05 to about 1 percent by weight of the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule.
19. The method according to claim 12, comprising from about 0.1 to about 0.5% percent by weight of the copper-zinc carboxylic acid salt having copper and zinc cations in the same molecule.
20. The method of claim 12 wherein the composition further comprises an active drug substance.
21. The method of claim 12 wherein the composition further comprises an active cosmetic substance.
22. The method of claim 12 wherein the composition further comprises humectant, solvent, water, or combinations thereof.
23. The method of claim 12 wherein the composition is in the form of a liquid, cream, oil, gel, fluid cream, lotion, emulsion or microemulsion.
Description
CROSS REFERENCE TO RELATED APPLICATION

This Application claims priority benefit of U.S. Provisional Application No. 60/764,967 filed Feb. 3, 2006 the entire disclosure of which is incorporated herein by this reference.

BACKGROUND

1. Technical Field

This disclosure relates to the use of compositions containing copper, zinc and/or copper-zinc active ingredients for pharmaceutical and cosmeceutical purposes.

2. Background of the Invention

Aging is a phenomenon which occurs in all living things. Unfortunately, with age comes a multitude of undesirable skin conditions which can adversely affect the appearance and health of skin. For example, as skin ages it becomes more susceptible to symptoms such as, inter alia, dryness, itchiness, thinning or thickening, wrinkles and/or fine lines, hyperpigmentation, telangietasias, and the like. Although there are known treatments for alleviating and curing age related skin conditions, known skin treatments are problematic in that results vary from patient to patient. Moreover, no one treatment, if ever, obtains maximum benefit for every patient. As a result, novel skin treatments are continuously sought after to thwart undesirable age related skin conditions.

Accordingly, there remains room for improvement in skin treatment regimens that enhance aged skin. What are needed are new skin care compositions and methods for treating age related skin conditions.

SUMMARY

Active ingredients such as copper-zinc salts of multifunctional organic acids and formulations containing them may be used to treat age related skin conditions. The copper constituent and zinc constituent, which may be cations, may be combined within a single molecule or used individually in separate molecules during topical application to treat age related skin conditions. For example, copper and zinc constituents may be topically applied simultaneously to the skin of the user in order to combine the catalytic properties of each constituent. Moreover, the copper and zinc constituents may be topically applied in the same molecule to combine the catalytic properties of each constituent. Accordingly, the combined application of copper and zinc constituents in the same topical treatment provides enhanced biological activity than the use of either constituent alone.

Skin having one or more undesirable age related conditions is treated in accordance with the present disclosure by the topical application of one or more active ingredients thereto. For example, compositions containing copper-zinc malonates can be directly applied to skin in need of treatment. Such conditioning by application of copper-zinc active ingredients may reduce or eliminate undesirable age related skin conditions, and promote or stimulate collagen, elastin, tropoelastin, and/or elastic fiber production in the dermis to make aged skin healthier, and/or appear younger.

In addition, dermatological treatment regimens in accordance with the present disclosure may improve characteristics of a user's aged skin. The regimens include the repeated topical application of one or more copper-zinc active ingredients. Suitable corrective compositions include, for example, compositions which help to reduce or eliminate age related conditions. In embodiments, compositions including a single molecule having both copper and zinc constituents are applied to the skin to increase levels of collagen, elastin, tropoelastin, and/or elastic fibers in the dermis layer. The resulting increase can improve the appearance of skin and/or give a more youthful look.

These and other aspects of this disclosure will be evident upon reference to the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a histogram comparing tropoelastin levels in skin after application of a 0.1% copper-zinc malonate formulation to skin at baseline (B) and at four weeks (C).

FIGS. 2A and 2B are photographs comparing elastic fibers in skin after application of a 0.1% copper-zinc malonate formulation to skin at baseline (FIG. 2A) and at four weeks (FIG. 2B).

FIGS. 3A, 3B and 3C are photographs that illustrate a comparison of wrinkles over treatment course which topically applied a composition in accordance with the present disclosure (0.1% copper-zinc malonate) to skin.

FIGS. 4A, 4B and 4C are photographs that illustrate a comparison of wrinkles over treatment course which topically applied a composition in accordance with the present disclosure (0.1% copper-zinc malonate) to skin.

FIGS. 5A, 5B and 5C are photographs that illustrate a comparison of wrinkles over treatment course which topically applied a composition in accordance with the present disclosure (0.1% copper-zinc malonate) to skin.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Active ingredients are used in accordance with the present disclosure to treat age related skin conditions. As copper and zinc are biologically needed by the body to catalyze the production of collagen and elastin in the dermis, active ingredients having copper, zinc and/or copper-zinc constituents can be topically applied to treat age related skin conditions. For example, bimetal complexes having copper and/or zinc constituents can be applied to skin to penetrate the dermis to stimulate production of collagen, elastin, tropoelastin and/or elastic fibers resulting in improved skin appearance.

Suitable active ingredients for use in accordance with the present disclosure include non-toxic compounds containing both copper and zinc. Such copper, zinc, and copper-zinc active ingredients include, but are not limited to, water soluble compounds that contain both copper and zinc. The water-soluble copper-zinc compounds include any copper-zinc salts formed from reacting any multifunctional organic or inorganic acid with any zinc or copper metal and/or their metallic bases. The organic acid can be aromatic or aliphatic. Suitable non-limiting examples of the water-soluble copper-zinc compounds include copper-zinc citrate, copper-zinc oxalate, copper-zinc tartarate, copper-zinc malate, copper-zinc succinate, copper-zinc malonate, copper-zinc maleate, copper-zinc aspartate, copper-zinc glutamate, copper-zinc glutarate, copper-zinc fumarate, copper-zinc glucarate, copper-zinc polyacrylic acid, and combinations thereof. Suitable non-water soluble copper-zinc compounds include any copper-zinc salts found from reacting any multifunctional water insoluble organic acid with zinc or copper metal and/or their metallic bases. Accordingly, suitable non-limiting examples of the non-water soluble copper-zinc compounds include copper-zinc adipate, copper-zinc pimelate, copper-zinc suberate, copper-zinc azelate, copper-zinc sebacate, copper-zinc dodecanoate, and combinations thereof. In embodiments, copper-zinc salts of organic multicarboxylic acids are suitable for use in accordance with the present disclosure. Accordingly, it is envisioned that multifunctional organic acids such as carboxylic acids may be reacted with any zinc or copper metal and/or their metallic bases to form the active ingredient of the present disclosure. In embodiments, the molar ratio of copper to zinc in the copper-zinc active ingredient is from about 1:1 to about 3:1. In other embodiments, the molar ratio of copper to zinc in the copper-zinc active ingredient is from about 1:1 to about 2:1.

In particular embodiments, non-limiting examples of suitable active ingredients include one or more copper-zinc malonates. As used herein “copper-zinc malonate” refers to any salt substances formed from malonic acid having copper and zinc constituents at various mole ratios of copper and zinc in the same molecule. For example, in embodiments, the molar ratio of copper to zinc in the copper-zinc malonate active ingredient is from about 1:1 to about 3:1. In other embodiments, the molar ratio of copper to zinc in the copper-zinc malonate active ingredient is from about 1:1 to about 2:1. In embodiments, copper-zinc malonate includes about 16.5% copper and about 12.4% zinc. In general, the copper-zinc malonate active ingredients used in accordance with the present disclosure include ingredients that are compounds of copper and zinc with malonic acid. Non-limiting examples of suitable ingredients for the formation of suitable copper-zinc malonates include, but are not limited to, malonic acid, zinc base, copper base, and water.

In forming suitable copper-zinc malonates for use in accordance with the present disclosure, malonic acid is present in amounts that will react with metal cations such as copper and zinc in an aqueous solution. Suitable amounts of malonic acid also include excess amounts in relation to the amount of copper and zinc cations to force reactions. In embodiments, malonic acid is present in a 3:1:1 molar ratio in relation to the copper and zinc constituents. Two or more salts containing copper and zinc constituents can be present in amounts that will react with malonic acid in an aqueous solution. Suitable salts that may be employed in making copper-zinc malonate active ingredients in accordance with this disclosure include metal salts containing complex-forming metal ions of copper and/or zinc. Non-limiting examples of suitable metal basic salts are: copper (I) and (II) salts such as copper carbonate, copper oxide, and copper hydroxide; and zinc salts such as zinc carbonate, zinc oxide, zinc hydroxide, metallic copper and metallic zinc. In embodiments, the reaction media includes two metallic salts, such as cupric carbonate (CuCO3.Cu(OH)2), zinc carbonate (3Zn(OH)2.2ZnCO3), or metallic zinc and metallic copper.

In embodiments, any copper salt, zinc salt and/or combinations of copper salt and zinc salt may be topically applied as an active ingredient in amounts sufficient to reduce or eliminate undesirable age related skin conditions, stimulate collagen, elastin tropoelastin and/or elastic fiber production in the dermis and/or make aged skin healthier and appear younger. Additional suitable non-limiting examples of copper and/or zinc salts which may be used to treat skin include copper (II) malonate and any hydrated form thereof such as copper (II) malonate dihydrate, copper (II) malonate trihydrate, and copper malonate tetrahydrate. Other suitable non-limiting examples of suitable copper and/or zinc salt active ingredients for treating age related skin conditions in accordance with the present disclosure include copper or zinc salts of citrate, oxalate, tartarate, malate, succinate, malonate, maleate, aspartate, glutamate, glutarate, fumarate, glucarate, polyacrylic acid, adipate, pimelate, suberate, azelate, sebacate, dodecanoate. Combinations thereof are also possible.

The active ingredient or ingredients may be combined with numerous ingredients to form products to be applied to the skin, or other tissues of humans or other mammals. Such products may include a dermatologically or pharmaceutically acceptable carrier or diluent, vehicle or medium, for example, a carrier, vehicle or medium that is compatible with the tissues to which they will be applied. The term “dermatologically or pharmaceutically acceptable,” as used herein, means that the compositions or components thereof so described are suitable for use in contact with these tissues or for use in patients in general without undue toxicity, incompatibility, instability, allergic response, and the like. In embodiments, compositions in accordance with the present disclosure can contain any ingredient conventionally used in cosmetics and/or dermatology.

As an illustrative example, compositions can be formulated to contain active ingredient in amounts from about 0.001 to about 5% by weight of the total composition. In embodiments, products can be formulated to contain active ingredient in an amount from about 0.05 to about 1% by weight of the total composition. In other embodiments, the amount of active ingredient is from about 0.1 to about 0.5% by weight of the total composition. In such embodiments, the copper or zinc salt and/or copper-zinc present may be in a pharmaceutically acceptable salt form.

In embodiments, products containing active ingredients in accordance with the present disclosure can be in the form of solutions, emulsions (including microemulsions), suspensions, creams, fluid cream, oils, lotions, gels, powders, or other typical solid or liquid compositions used for treatment of age related skin conditions. Such compositions may contain, in addition to the copper and/or zinc salts and/or copper-zinc salts in accordance with this disclosure, other ingredients typically used in such products, such as other active cosmetic substances such as retinol, retinol derivatives, allantoin, tocopherol, tocopherol derivatives, niacinamide, phytosterols, isoflavones, panthenol, panthenol derivatives, bisabolol, farnesol, and combinations thereof, other active drug substances such as corticosteroid, metronidazole, sulfacetamide, sulfur, and combinations thereof, antioxidants, antimicrobials, coloring agents, detergents, dyestuffs, emulsifiers, emollients, fillers, fragrances, gelling agents, hydration agents, moisturizers, odor absorbers, natural or synthetic oils, penetration agents, powders, preservatives, solvents, surfactants, thickeners, viscosity-controlling agents, water, distilled water, waxes, and optionally including anesthetics, anti-itch actives, botanical extracts, conditioning agents, darkening or lightening agents, glitter, humectant, mica, minerals, polyphenols, phytomedicinals, silicones or derivatives thereof, skin protectants, sunblocks, vitamins, and mixtures or combinations thereof. Such compositions may also contain, in addition to the copper or zinc salts and/or copper-zinc salts in accordance with this disclosure, one or more: fatty alcohols, fatty acids, organic bases, inorganic bases, wax esters, steroid alcohols, triglyceride esters, phospholipids, polyhydric alcohol esters, fatty alcohol ethers, hydrophilic lanolin derivatives, hydrophilic beeswax derivatives, cocoa butter waxes, silicon oils, pH balancers, cellulose derivatives, hydrocarbon oils, or mixtures and combinations thereof.

In embodiments, product forms can be formulated to contain humectant in amounts from about 1% to about 15% by weight of the total composition. For example glycerine can be added to the composition in amounts from about 1% to about 15% by weight of the total composition. In particular embodiments, glycerine can be added to the composition in amounts from about 1% to about 5% by weight of the total composition.

In embodiments, product forms can be formulated to contain solvent in amounts from about 1% to about 45% by weight of the total composition. For example petroleum derivatives such as propylene glycol can be added to the composition in amounts from about 1% to about 45% by weight of the total composition. In particular embodiments, propylene glycol can be added to the composition in amounts from about 15% to about 30% by weight of the total composition.

In embodiments, product forms can be formulated to contain water in amounts from about 40% to about 99% by weight of the total composition. For example distilled water can be added to the composition in amounts from about 40% to about 99% by weight of the total composition. In particular embodiments, distilled water can be added to the composition in amounts from about 65% to about 80% by weight of the total composition.

The present active ingredients and formulations containing them in accordance with the present disclosure can be topically applied to skin in need of improvement in amounts sufficient to reduce or eliminate undesirable age related skin conditions, such as via stimulation of collagen, elastin, tropoelastin and/or elastic fiber production. As used herein the word “treat,” “treating” or “treatment” refers to using the compositions of the present disclosure prophylactically to prevent outbreaks of any undesirable age related skin conditions, or therapeutically to ameliorate an existing undesirable age related skin condition. A number of different treatments are now possible, which reduce and/or eliminate age related skin conditions such as wrinkles.

As used herein “age related skin condition” refers to any detectable skin manifestations caused by skin aging. Such manifestations can appear due to a number of factors such as, for example, chronological aging, environmental damage, and/or other diseased or dysfunctional state. Non-limiting examples of such manifestations include the development of dryness, itchiness, thinning, thickening, wrinkling, including both fine superficial wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores, scaliness, flakiness and/or other forms of skin unevenness or roughness, hyperpigmentation, mottled appearance, decreased healing times, cherry angioma, telangietasias, senile development, actinic purpura development, seborrheic keratoses, actinic keratoses, fatty tissue formation, fatty tissue deterioration, increased collagen, elastin, tropoelastin, and elastic fiber content, decreased collagen, elastin, tropoelastin or elastic fiber content, and combinations thereof. Such manifestations further include undesirable tactile conditions such as loss of skin elasticity, sagging, loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, and/or sallowness. Such manifestations further include undesirable visible conditions such as hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratinization, stretch marks, discoloration, blotching, and combinations thereof. It is understood, that the listed age related skin conditions are non-limiting and that only a portion of the skin conditions suitable for treatment in accordance with the present disclosure are listed herein.

In embodiments, compositions for use in accordance with the present disclosure contain one or more active ingredients capable of contacting skin with copper and/or zinc in an effective amount to improve undesirable age related skin conditions. As used herein “effective amount” refers to an amount of a compound or composition having active ingredients such as those having copper, zinc and/or copper-zinc constituents in accordance with the present disclosure that is sufficient to induce a particular positive benefit to skin having an age related skin condition. The positive benefit can be health-related, or it may be more cosmetic in nature, or it may be a combination of the two. In embodiments, the positive benefit is achieved by contacting skin with a combination of copper and zinc which can be in the form of copper and zinc ions, and/or one or more salts having copper and zinc constituents, to improve an age related skin condition. In embodiments, the positive benefit is achieved by contacting skin with one or more active ingredients to enhance tropoelastin levels and/or increase insoluble elastic fibers in skin. In embodiments, the positive benefit is achieved by contacting skin with one or more active ingredients to increase insoluble elastin levels and/or reestablish firmness of skin. In embodiments, the positive benefit is achieved by contacting skin with one or more active ingredients to improve wrinkles.

The particular active ingredient or ingredients employed, and the concentration in the compositions, generally depends on the purpose for which the composition is to be applied. For example, the dosage and frequency of application can vary depending upon the type and severity of the age related skin condition.

Treatments in accordance with the present disclosure contact skin with one or more active ingredients such as those containing copper and zinc in an effective amount to improve undesirable age related skin conditions. In embodiments, patients are treated by topically applying to skin suffering from an age related condition, one or more copper-zinc malonates. In embodiments, patients are treated by topically applying to skin suffering from an age related condition, one or more copper, zinc and/or copper-zinc salts. The active ingredient is applied until the treatment goals are obtained. However, the duration of the treatment can vary depending on the severity of the condition. For example, treatments can last several weeks to months depending on whether the goal of treatment is to reduce or eliminate an age related skin condition.

Treatments in accordance with the present disclosure contact skin with one or more active ingredients such as those containing copper and zinc in an effective amount to increase collagen, elastin (insoluble/soluble), elastic fiber and/or tropoelastin levels therein. As used herein “elastin” refers to a protein in the skin that helps maintain resilience and elasticity. Generally, elastin is a protein in connective tissue that is elastic and allows tissues in the body, including skin, to resume their shape after stretching or contracting. For example, when pressure is applied to skin to change its shape, elastin helps skin to return to its original shape. Elastin may be made by linking multiple tropoelastin protein molecules to make a large insoluble cross-linked aggregate. As used herein “tropoelastin” refers to a water-soluble precursor to the elastin molecule, having a molecular weight of about 70000 Daltons. As used herein, “collagen” refers to a fibrous protein that contributes to the physiological functions of connected tissues in the skin, tendon, bones, and cartilage. Generally, the structural unit is tropocollagen composed of 3-polypeptide chains, designated A1, A2, and A3 that form a triple helical structure stabilized by hydrogen bonds. The term collagen further refers to collagen types, such as type I collagen, type II collagen, and type III collagen.

In embodiments, patients are treated by topically applying to skin in need of collagen, elastin, tropoelastin and/or elastic fibers one or more copper, zinc and/or copper-zinc salts, such as copper-zinc malonate. The active ingredient is applied until the treatment goals are obtained. However, the duration of the treatment can vary depending on the severity of the condition. For example, treatments can last several weeks to months depending on whether the goal of treatment is to promote or repair collagen, elastin, tropoelastin and/or elastic fiber levels in the skin. In treatment embodiments, 1 to 5 drops of a composition containing 0.1% copper-zinc malonate may be applied to wrinkled skin twice a day for 4 weeks. In such treatments, some users should expect tropoelastin levels in the skin to increase in amounts of about 5% to about 30% and/or insoluble elastin content to be increased in amounts of about 20% to about 30%. Accordingly, some users should expect the treatment to diminish wrinkles and cause the skin to appear healthier and look younger. Moreover, some users should expect firmness of the wrinkled skin to be reestablished.

In embodiments, the active agents are applied for cosmetic purposes only.

In some embodiments, use of a compound including copper-zinc ingredients such as copper-zinc malonate may be included in the manufacture of a medicament for treatment of an age related skin condition. In such embodiments, copper-zinc ingredients described in accordance with the present disclosure can be manufactured into a pure medicament, compositions containing medicament, and/or formulations containing medicament and any excipients and/or ingredients described herein.

The following non-limiting examples further illustrate methods in accordance with this disclosure.

Example 1

A 72 year old woman is suffering from wrinkling on her face. A gel composition suitable for treatment of skin containing an effective amount of copper-zinc malonate active ingredient is routinely applied to her face twice daily. Wrinkling is reduced or eliminated.

Example 2

A copper-zinc malonate formulation has the following make-up:

COMPONENT % BY WEIGHT
Copper-zinc malonate* 0.1%
(Active ingredient)
Glycerine 3.0%
Propylene Glycol 25.0%
Distilled Water 71.9%
*Copper-zinc malonate was made by mixing 1 mole Zn/1 mole Cu/3 moles malonic acid.

Example 3

A 28-day, split-face, right and left forearm punch biopsy study to investigate the efficacy of composition of Example 2 to increase the collagen, elastin, tropoelastin and/or elastic fiber levels in the skin was performed. Pre-determined treatment areas were assigned around eyes and on forearms.

The following application protocol was used on some subjects:

Treatment Protocol:

A trained technician applied the composition of Example 2 to pre-assigned eye areas and forearm areas wearing a clear polyethylene disposable glove to rub product uniformly onto the test site. Product and total amounts applied were:

Formulation of Example 2 applied to eye area 1 drop
Formulation of Example 2 applied to forearm 2 drops
Formulation of Example 2 without active applied to eye area 1 drop
Formulation of Example 2 without active applied to forearm 2 drops

After application, the subjects were instructed to avoid washing areas for a minimum of 8 hours.

Treatments for all subjects included daily product applications (Monday-Friday) at the clinic starting at baseline (Day 1) through Day 27. Skin elasticity measurements were taken by a trained technician using the Cutometer® (Courage+Khazaka) as well as ultrasound recordings. Cutometer and ultrasound measurements were taken at baseline (Day 1), week 2 (Day 14), and week 4 (Day 28). Punch biopsy skin samples were obtained at baseline and at week 4 (Day 28) on the right and left forearms of some subjects. A total of 2 punch biopsies (1 on the right forearm and 1 on the left forearm) were taken by a Board Certified Dermatologist at each visit.

Results:

Individuals that utilized the formulation of example 2 (with active ingredient) show increased levels tropoelastin and elastic fibers in skin after 27 days of product application. For example, elevated levels of tropoelastin were observed. Referring to FIG. 1, a histogram compares tropoelastin levels at baseline (B) and at four weeks (C). The results demonstrate that the application of copper-zinc malonate composition of Example 2, increases tropoelastin levels by approximately 19%. Moreover, for 8 of 13 subjects where composition of Example 2 with active ingredient was applied to the forearm, an increase in insoluble elastic fibers of approximately 29% was observed.

Referring now to FIGS. 2A and 2B, photographs of skin tissue comparing elastic fibers at baseline (arrow in FIG. 2A) to elastic fibers after four weeks (arrow in FIG. 2B) are shown. Accordingly, treatment with composition in accordance with Example 2 increased elastic fibers in skin.

Referring now to FIGS. 3A, 3B, and 3C, a series of progressive photographs are shown of the face of a 67 year old female having Fitzpatrick Type I skin type at baseline, two weeks, and 4 weeks respectively during treatment in accordance with the present disclosure. Here, the treatment included applying 1 drop of a formulation in accordance with Example 2 to skin immediately adjacent to the right eye (O.D.). The photographs show reduced wrinkling of skin around the right eye where composition in accordance with the present disclosure (Example 2) was applied. Skin in FIG. 3C after four weeks of treatment looked healthier and younger and reduced wrinkling was observed.

Referring now to FIGS. 4A, 4B, and 4C a series of progressive photographs are shown of the face of a 50 year old female having Fitzpatrick Type I skin type at baseline, two weeks, and 4 weeks respectively during treatment in accordance with the present disclosure. Here, the treatment included applying 1 drop of a formulation in accordance with Example 2 to skin immediately adjacent to the left eye (O.S.). The photographs show reduced wrinkling of skin around the left eye where composition in accordance with the present disclosure (Example 2) was applied. Skin in FIG. 4C after four weeks of treatment looked healthier and younger and reduced wrinkling was observed.

Referring now to FIGS. 5A, 5B, and 5C a series of progressive photographs are shown of the face of a 59 year old female having Fitzpatrick Type I skin type at baseline, two weeks, and 4 weeks respectively during treatment in accordance with the present disclosure. Here, the treatment included applying 1 drop of a formulation in accordance with Example 2 to skin immediately adjacent to the right eye (O.D.). The photographs show reduced wrinkling of skin around the right eye where composition in accordance with the present disclosure (Example 2) was applied. Skin in FIG. 5C after four weeks of treatment with composition of Example 2 looked healthier and younger and reduced wrinkling was observed.

While several embodiments of the disclosure have been described, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US46494Feb 21, 1865 Improved eye-water
US51868Jan 2, 1866 Improved remedy for sore eyes
US55889Jun 26, 1866 Improved eye-water
US81008Aug 11, 1868 Improved eye-wateb
US81711Sep 1, 1868 Improved m medical compound for treating horses, cattle
US87343Mar 2, 1869 Improved medical compound
US88973Apr 13, 1869 Improved salve for cure of foot-rot in sheep
US92065Jun 29, 1869 Improved compound to be used in the cure op rheumatism
US93300Aug 3, 1869 Improved eye-sirup
US116875Jul 11, 1871 Improvement in medical compounds
US124751Mar 19, 1872 Improvement in medical compounds or salves
US127925Jun 11, 1872 Improvement in medical compounds for treating ringworm
US128385Jun 25, 1872 Improvement in medical compounds
US140768Oct 5, 1872Jul 15, 1873 Improvement in eye-washes
US143133Sep 12, 1873Sep 23, 1873 Improvement in medical compounds or powders for infants
US145749Dec 23, 1873 Improvement in medical compounds or eye-washes
US149857Jan 21, 1874Apr 21, 1874 Improvement in medical compounds or liniments
US171875Aug 11, 1875Jan 4, 1876 Improvement in cattle-washes
US173607Feb 15, 1876 Improvement in deodorizing, disinfecting, and antiseptic powders
US209331Jun 19, 1878Oct 29, 1878 Improvement in medical compounds
US229014Apr 26, 1880Jun 22, 1880 Salve
US232807Oct 5, 1880 Herbert e
US238015May 24, 1880Feb 22, 1881 Ointment
US264783Jan 20, 1882Sep 19, 1882 Eye-wash
US277221Mar 6, 1883May 8, 1883 Cosmetic wash
US284335Mar 8, 1883Sep 4, 1883 Eye-water
US318468Mar 19, 1885May 19, 1885 Eye remedy
US320836Jun 23, 1885 Ointment
US411657Jul 8, 1889Sep 24, 1889 Lotion
US415208Nov 19, 1889 Ointment
US430048Jul 19, 1889Jun 10, 1890 Medical bandage
US432611Dec 27, 1889Jul 22, 1890 Salve
US627296Jun 20, 1899 Arthur camnitzer
US928539Apr 16, 1908Jul 20, 1909Gennaro PucciarelliLotion.
US944738Aug 16, 1909Dec 28, 1909Windeler LooseMedicament for diseases of the mucous membrane.
US992937Dec 23, 1909May 23, 1911Brodbeck CompanyNursery-powder compound.
US1059841Sep 23, 1912Apr 22, 1913Henry CrookesProduction of colloidal metals.
US1086900Feb 28, 1913Feb 10, 1914Kalil DavidRemedy for syphilis.
US1332190Jun 21, 1918Feb 24, 1920Meda Mfg CompanyCosmetic
US1411577Feb 23, 1921Apr 4, 1922Collier William ROintment
US1488097Mar 9, 1922Mar 25, 1924Creger Henry NDentifrice
US1584173Dec 5, 1925May 11, 1926Albert C HolzapfelAntiseptic
US1593485Aug 21, 1925Jul 20, 1926Crosnier Georges Eugene EdmeAntiseptic product
US1627963Jan 30, 1920May 10, 1927Fuller Henry CMedicinal product
US1809082May 4, 1927Jun 9, 1931Epstein & HarrisProduct for treating the skin
US1908176May 28, 1929May 9, 1933Chemical Foundation IncProcess of making a purified coal tar ointment
US1947568Sep 27, 1930Feb 20, 1934Drug Products Co IncCarron oil compound chlorinated cream
US1949797Nov 11, 1932Mar 6, 1934Kaufmann HansProcess of producing compositions of matter containing sulphur in colloidal distribution
US1982148Aug 22, 1932Nov 27, 1934Zimbron Jr AngelMedicament for external use and method of producing the same
US2002829Apr 21, 1933May 28, 1935Chemical Foundation IncMedicinal preparation
US2054989Dec 30, 1933Sep 22, 1936Us Ind Alcohol CoCompositions for application to the human skin
US2087162Nov 25, 1935Jul 13, 1937Us Ind Alcohol CoPerspiration-inhibiting composition
US2095092Feb 21, 1936Oct 5, 1937Clorox Chemical CoOintment
US2114490Sep 27, 1937Apr 19, 1938Harris Benjamin REmulsion
US2129836Jul 2, 1936Sep 13, 1938Cosmetic Res IncCosmetic cream rase
US2153653Jan 8, 1936Apr 11, 1939Gustav StuxIrradiated dusting powder
US2194218Sep 13, 1937Mar 19, 1940Dickeson Thurstan WyattStable emulsions of water with liquid or liquefiable substances which are immiscible with water
US2223142Jul 11, 1938Nov 26, 1940C B Dolge CompanyFungicidal preparation
US2241331Jan 27, 1939May 6, 1941Wm S Merrell CoSuppository
US2254636May 11, 1938Sep 2, 1941Vangunten Verl DMedicinal product
US2267739Apr 5, 1938Dec 30, 1941George B WhiteComposition of matter for treating skin diseases
US2289125Apr 18, 1938Jul 7, 1942Wilfred B KellTherapeutic agent for the treatment of fungus infection
US2299604Dec 1, 1939Oct 20, 1942C B Doige CompanyFungicidal composition
US2344830Aug 15, 1940Mar 21, 1944Wisconsin Alumni Res FoundComposition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US2361161Sep 21, 1943Oct 24, 1944Charles Anderson DavidBasic filling for tooth cavities
US2370561Jul 11, 1941Feb 27, 1945Schuylkill Chemical CoTherapeutic product and method of making same
US2372807Jul 5, 1941Apr 3, 1945Atlas Powder CoAbsorption bases
US2420271May 18, 1944May 6, 1947Jones Howard AInsect repellent composition
US2420389Mar 21, 1947May 13, 1947Jones Howard AInsect repellent composition
US2469228Feb 18, 1946May 3, 1949Gertler Samuel IInsect repellent
US2527686Dec 26, 1945Oct 31, 1950Sandberg Max HMouthwash
US2556567Apr 1, 1949Jun 12, 1951Tampax IncDouche composition
US2602039May 24, 1950Jul 1, 1952Dome Chemicals IncCrude coal tar dermatological compositions
US2649398Apr 1, 1949Aug 18, 1953Tampax IncDouche composition
US2652355Jan 31, 1950Sep 15, 1953Warner Hudnut IncFungicides
US2673364May 4, 1948Mar 30, 1954Twix IncDental cleaning pad
US2703777May 2, 1950Mar 8, 1955Iso Sol Company IncOphthalmological preparations and vehicles and method of making the same
US2736681Feb 11, 1955Feb 28, 1956Merck & Co IncChemical compounds
US2748781Aug 24, 1953Jun 5, 1956Edgar CollatMeans for dental hygiene
US2838440Oct 29, 1953Jun 10, 1958Rohm & HaasDusting powder of carboxylic cationexchange resin and powder base
US2843522Nov 17, 1953Jul 15, 1958Sterling Drug IncPeri-anal ointment
US2846322Apr 29, 1952Aug 5, 1958Edgar SchaeferBactericidal dental cements
US2870150Nov 29, 1954Jan 20, 1959Abbott LabMorpholine ethers
US2870151Nov 29, 1954Jan 20, 1959 Mqrpholine -ethers
US2872372May 21, 1957Feb 3, 1959Ici LtdNew indole derivatives
US2991224Aug 18, 1958Jul 4, 1961Bell Dale VGingival pack
US3013883Oct 17, 1960Dec 19, 1961Clyde J WelckerProcess for chemically opening bivalves
US3033755Apr 14, 1961May 8, 1962Kolmar LaboratoriesProcess for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom
US3035988Mar 19, 1958May 22, 1962Dover Chemical CorpMethod of forming friction film on hand
US3084105May 24, 1961Apr 2, 1963Morey E SlodkiDispersants comprising phosphoric acid monoesters of mannose polymers
US3137622Dec 23, 1957Jun 16, 1964KlineTopical therapeutic composition
US3146168Apr 10, 1962Aug 25, 1964Fmc CorpManufacture of pharmaceutical preparations containing cellulose crystallite aggregates
US3164523Mar 22, 1961Jan 5, 1965Warner Lambert PharmaceuticalComposition for skin beautification and treatment
US3184376Apr 16, 1962May 18, 1965 Method of producing antiseptic composition
US3210248Sep 4, 1963Oct 5, 1965Merck & Co IncEmollient gel comprising lanolin alcohol, microcrystalline wax and a liqquid fatty acid ester
US3215599Jul 2, 1963Nov 2, 1965Warner Lambert PharmaceuticalProcess for preparing polymer waxmodified petroleum oil unctuous base
US3255079Jun 17, 1963Jun 7, 1966American Cyanamid CoTherapeutic dental cement and a method for treating carious teeth
US3290218May 9, 1963Dec 6, 1966De Jong Elkan JoachimStable pharmaceutical and cosmetic dispersions
US3317372Sep 29, 1965May 2, 1967Hart Una LHousehold deodorant
US3366114Jun 29, 1964Jan 30, 1968Saul L. KanterIleostomy appliance
US3590123Mar 9, 1967Jun 29, 1971Rewo Chem Fab GmbhHuman hair,skin and nail treatment with sulfosuccinate compositions
US3749772Dec 4, 1970Jul 31, 1973Univ AkronDermal protective film
US3821370Mar 11, 1971Jun 28, 1974L TentaTopical composition for treating seborrheic keratosis
US3821371Jul 24, 1972Jun 28, 1974Avicon IncPharmaceutical compositions containing microcrystalline collagen,a water-insoluble,ionizable,partial salt of collagen
US3826845Feb 4, 1970Jul 30, 1974Sankyo CoOintment base
US3856941May 23, 1972Dec 24, 1974Sobel JAstringent gel, its preparation and use
US3896238Mar 13, 1973Jul 22, 1975Procter & GambleDermatological compositions
US3903268Feb 19, 1971Sep 2, 1975Lescarden LtdChitin and chitin derivatives for promoting wound healing
US3949072May 1, 1974Apr 6, 1976Tenta Louis TTopical composition for treatment of seborrheic keratosis
US4048300Jan 19, 1976Sep 13, 1977Colgate-Palmolive CompanyDental preparation containing materials having calcium and phosphate components
US4100269May 6, 1977Jul 11, 1978Lever Brothers CompanyAnticalculus dentifrice
US4138477May 28, 1976Feb 6, 1979Colgate Palmolive CompanyComposition to control mouth odor
US4146607Nov 7, 1977Mar 27, 1979Lever Brothers CompanySynergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc
US4154911 *Jun 12, 1978May 15, 1979Mooney Chemicals, Inc.Elastomers with improved metal adhesion
US4160821Feb 27, 1978Jul 10, 1979Johnson & JohnsonTreatment for gingivitis
US4161526Jul 20, 1978Jul 17, 1979Sterling Drug Inc.Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions
US4166108Aug 18, 1977Aug 28, 1979Robert BrownStyptic composition
US4226851Jul 11, 1979Oct 7, 1980Sompayrac Hewitt AStable dental composition containing hydrogen peroxide
US4226889Dec 19, 1978Oct 7, 1980Dragoco, Inc.Cosmetic stick composition
US4229430Aug 21, 1978Oct 21, 1980Fahim Mostafa SOral composition for improving oral health
US4229437Jul 18, 1978Oct 21, 1980Lucille Likens FilsonPaste or dough-like salve for treating skin
US4255418May 14, 1979Mar 10, 1981Bailey Florence HAnti-acne lotion
US4273763Jan 19, 1979Jun 16, 1981Efamol LimitedPharmaceutical and dietary compositions
US4285967Feb 4, 1980Aug 25, 1981Estee Lauder Inc.Cosmetic preparation for reducing redness of blemishes
US4291025Apr 11, 1980Sep 22, 1981Laclede Professional Products, Inc.Agar gel topical dressing
US4298601Jul 24, 1978Nov 3, 1981Technutra, S.A.Method and formulations for the treatment of obesity
US4302447Oct 30, 1979Nov 24, 1981Efamol LimitedPharmaceutical and dietary composition
US4305842 *Feb 8, 1980Dec 15, 1981Mitsubishi Gas Chemical Company, Inc.Preparation of improved catalyst composition
US4309989Aug 14, 1978Jan 12, 1982The Curators Of The University Of MissouriTopical application of medication by ultrasound with coupling agent
US4310516Feb 1, 1980Jan 12, 1982Block Drug Company Inc.Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4315916Dec 28, 1979Feb 16, 1982Lucille L. FilsonTopical salve
US4322400Sep 18, 1979Mar 30, 1982Dragoco Inc.Cosmetic stick composition
US4330527Nov 13, 1979May 18, 1982Teruo ArimaWound treatment agent
US4331653May 11, 1979May 25, 1982Robert BrownComposition for a topical cream for curtailing bleeding and treating skin disorders
US4335110Aug 18, 1980Jun 15, 1982Orewa Inc.Pharmaceutical compositions of sanguinaria galangal and zinc chloride
US4349536Apr 20, 1981Sep 14, 1982Hausler Kenneth JMethod of promoting suntan using a cream containing zinc and copper salts
US4372296Nov 26, 1980Feb 8, 1983Fahim Mostafa STreatment of acne and skin disorders and compositions therefor
US4375968Jul 10, 1981Mar 8, 1983Manhart Mark JTherapeutic calcium hydroxide dental preparation and method
US4376115Sep 25, 1981Mar 8, 1983Mccrorey Howard SMethod and composition for treating teeth and method for preparing same
US4395398Mar 31, 1981Jul 26, 1983Bee Brand Medico Dental Co., Ltd.Dental hemostatic composition
US4406881Sep 18, 1981Sep 27, 1983Vipont LaboratoriesAntimicrobial agent
US4428933Aug 2, 1982Jan 31, 1984King John RComposition for treating acne, method of manufacturing said composition, and method of treating skin
US4430324Sep 7, 1982Feb 7, 1984Lever Brothers CompanyAmmonium fluorometallate containing compositions
US4444755Jun 10, 1981Apr 24, 1984Efamol LimitedTreatment for skin disorders
US4465666Oct 30, 1981Aug 14, 1984Ciba-Geigy CorporationNew pharmaceutical preparations
US4469684Oct 15, 1982Sep 4, 1984The Procter & Gamble CompanyStorage stable topical pharmaceutical composition containing zinc erythromycin and low dielectric solvents
US4477439Apr 13, 1981Oct 16, 1984Walter J. MonacelliTreatment of irritated and excoriated areas around the stoma of ostomy patients
US4486488Mar 17, 1983Dec 4, 1984Beiersdorf AktiengesellschaftComposition for the production of bandages, bandages produced therewith and method for the production thereof
US4503037Sep 21, 1982Mar 5, 1985Human Oltoanyagtermel/o/ es Kutato IntezetComposition for the treatment of epithelial injuries and process for the preparation thereof
US4512978Oct 15, 1982Apr 23, 1985Inwood Louis RDermatological composition useful in the treatment of psoriasis
US4515779Oct 23, 1981May 7, 1985Arkansas Medical Research & Development CorporationSkin tumor removal and healing compositions and processes
US4522806Dec 19, 1983Jun 11, 1985Lever Brothers CompanyOral compositions for hexetidine and zinc salts for the synergistic inhibition of dental plaque
US4568540Apr 18, 1984Feb 4, 1986Johnson & JohnsonOral hygiene compositions
US4604234Feb 28, 1984Aug 5, 1986Sanwa Kagaku Kenyusho Co., Ltd.Protein having cell growth stimulating action, composition thereof and method for producing the same
US4606920Mar 2, 1984Aug 19, 1986Walter Hans PeterPharmaceutical composition suitable for treatment of inflammatory changes of the bronchial mucosa
US4647452Nov 8, 1985Mar 3, 1987Lever Brothers CompanyOral compositions of salicylamides and zinc salts for the synergistic inhibition of dental plaque
US4654213Sep 11, 1985Mar 31, 1987Cheesebrough-Pond's Inc.Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt
US4661354Aug 2, 1985Apr 28, 1987Finnerty Edmund FTopical treatment of herpes simplex with a zinc sulfate-camphor water solution
US4665054Feb 8, 1985May 12, 1987Bioheal, Inc.Chemical derivatives of GHL-Cu
US4678664Sep 30, 1982Jul 7, 1987Basf CorporationMineral oil gels
US4683133Aug 20, 1985Jul 28, 1987Vipont Laboratories, Inc.Method for treating periodontal disease
US4713242Nov 7, 1985Dec 15, 1987Tecma Laboratories, Inc.Skin therapeutic mixture containing eupatorium extract
US4760051Jan 24, 1985Jul 26, 1988Pickart Loren RUse of GHL-Cu as a wound-healing and anti-inflammatory agent
US4762715Oct 15, 1987Aug 9, 1988Ciba-Geigy CorporationAntiherpetically active lipstick and the use thereof for the treatment of disorders of the lips and other areas of the face casued by human herpes viruses
US4767753May 11, 1987Aug 30, 1988Procyte CorporationMethods and compositions for preventing ulcers
US4810693May 11, 1987Mar 7, 1989Procyte CorporationMethod for inducing biological coverings in wounds
US4816254Jul 29, 1987Mar 28, 1989Moss Thomas DOintment for treating skin irritations
US4847083Feb 27, 1987Jul 11, 1989Dermasciences, Inc.Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith
US4849211Mar 16, 1988Jul 18, 1989Schrauzer Gerhard NProduct and method for the treatment of acne and other skin disorders
US4855138Jun 24, 1986Aug 8, 1989Tecma Laboratories, Inc.Skin therapeutic mixture containing matico extract
US4863897 *Aug 3, 1987Sep 5, 1989Caola Kozmetikai Es Haztartasvegyipari VallalatProtein and mineral water-containing cosmetic compositions
US4863987Nov 10, 1986Sep 5, 1989Dainichiseika Color & Chemicals Mfg. Co., Ltd.Deodorizing coating formulations and deodorizing sheets making use of same
US4874361Dec 29, 1986Oct 17, 1989Obagi Zein EMethod for healing damaged skin
US4877770Feb 17, 1989Oct 31, 1989Procyte CorporationChemical derivatives of GHL-Cu
US4895727May 3, 1985Jan 23, 1990Chemex Pharmaceuticals, Inc.Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4911932Feb 11, 1985Mar 27, 1990Johnson And Johnson Consumer Products, Inc.Skin care compositions
US4937230Dec 4, 1987Jun 26, 1990Procyte CorporationMethod of healing wounds in horses
US4938969Nov 14, 1988Jul 3, 1990Milor Scientific, Ltd.Method for the treatment of aging or photo-damaged skin
US4956354Dec 6, 1988Sep 11, 1990Thomas G. KottkeTherapeutic preparation for use on skin
US4992259Jan 3, 1990Feb 12, 1991Johnson & Johnson Consumer Products, Inc.Stable oral composition of zinc
US5000944Jun 9, 1989Mar 19, 1991Colgate-Palmolive CompanyZinc-containing oral products with reduced astringency
US5023237Aug 30, 1989Jun 11, 1991Procyte CorporationMethods and compositions for healing ulcers
US5059588Oct 13, 1989Oct 22, 1991Procyte Corporation, IncorporatedMethods and compositions for healing bone using gly his lys: copper
US5075469Jul 10, 1990Dec 24, 1991Yissum Research Development Company Of The Hebrew University Of JerusalemPharmaceutical compositions containing a zinc complex
US5079010Sep 22, 1989Jan 7, 1992Siegfreid NattererPharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals
US5091171Aug 15, 1989Feb 25, 1992Yu Ruey JAmphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US5091193Aug 21, 1990Feb 25, 1992Roussel UclafDiaper rash treatment and compositions
US5093099Nov 14, 1988Mar 3, 1992Kao CorporationFlaky powder of zinc oxide and its composition for external use
US5104644Oct 25, 1990Apr 14, 19927-L CorporationMouthrinse composition
US5118665Feb 9, 1990Jun 2, 1992Procyte CorporationAnti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof
US5120831Nov 13, 1989Jun 9, 1992Procyte CorporationMetal-peptide compositions
US5135913Jun 16, 1988Aug 4, 1992Procyte CorporationCosmetic and skin treatment compositions
US5145838Jun 10, 1991Sep 8, 1992Procyte CorporationMethods and compositions for healing ulcers
US5154932Sep 4, 1990Oct 13, 1992The Dow Chemical CompanyAntimicrobial positively charged particles
US5164367Mar 26, 1990Nov 17, 1992Procyte CorporationMethod of using copper(ii) containing compounds to accelerate wound healing
US5165914Oct 22, 1991Nov 24, 1992David G. VlockOral compositions containing zinc lactate complexes
US5166176Mar 24, 1989Nov 24, 1992Obagi Zein EComposition for healing damaged skin
US5174990Sep 5, 1991Dec 29, 19927-L CorporationMouthrinse and method of preparation
US5177061Sep 22, 1989Jan 5, 1993Procyte CorporationMethod for stimulating hair growth using GHL-Cu complexes
US5209932Apr 24, 1992May 11, 1993Moleculon, Inc.Foot care compositions
US5214032Jun 16, 1992May 25, 1993Procyte CorporationGHL-CU pharmaceutical compositions and compounds
US5227156Apr 14, 1992Jul 13, 1993Amway CorporationUse of zinc compounds to stabilize a thiazolinone preservative in an anti-dandruff shampoo
US5232691May 22, 1991Aug 3, 1993Lemole Gerald MProtective gel composition
US5240696Aug 5, 1992Aug 31, 1993Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.Treatment of periodontitis
US5244651Sep 4, 1992Sep 14, 1993Kao CorporationMethod of desensitizing hypersensitive dentin
US5258183Jul 24, 1992Nov 2, 1993Grimberg Georges SergeMedicine based on neutralized sulphur derivatives
US5310546Dec 24, 1992May 10, 19947-L CorporationMouthrinse and method of preparation
US5330748May 19, 1993Jul 19, 1994Church & Dwight Co., Inc.Dentifrices containing zinc oxide particles
US5330749Aug 31, 1993Jul 19, 1994Church & Dwight Co., Inc.Liquid mouthwash containing a particulate bicarbonate suspension
US5348943Aug 3, 1992Sep 20, 1994Procyte CorporationCosmetic and skin treatment compositions
US5352438 *Apr 30, 1992Oct 4, 1994L'orealAnti-free radical topical composition based on dismutase superoxide and a phosphonic derivative
US5382431Sep 29, 1992Jan 17, 1995Skin Biology, Inc.Tissue protective and regenerative compositions
US5385727May 19, 1993Jan 31, 1995Church & Dwight Co., Inc.Dentifrices containing zinc oxide particles and sodium bicarbonate
US5401730Apr 22, 1993Mar 28, 1995The Hope Heart InstituteMethod for reducing platelet aggregation
US5424077Jul 13, 1993Jun 13, 1995Church & Dwight Co., Inc.Co-micronized bicarbonate salt compositions
US5439863Sep 9, 1993Aug 8, 1995Rutgerswerke AktiengesellschaftNeutral metal complex salts
US5455023Mar 30, 1994Oct 3, 1995Church & Dwight Co., Inc.Liquid mouthwash containing a particulate bicarbonate suspension
US5466470May 25, 1994Nov 14, 1995Church & Dwight Co., Inc.Co-micronized bicarbonate salt compositions
US5480975Feb 8, 1994Jan 2, 1996Brigham And Women's HospitalInduction of vascular endothelial growth factor (VEGF) by transition metals
US5482720Oct 11, 1994Jan 9, 1996Church & Dwight Co., Inc.Encapsulated co-micronized bicarbonate salt compositions
US5484597 *Jul 30, 1993Jan 16, 1996Chesebrough-Pond's Usa Co.Clear hydroalcholic cosmetic microemulsions
US5500448May 12, 1994Mar 19, 1996Chesebrough-Pond's Usa Co., Division Of Conopoco, Inc.Recurrent aphthous ulcer treatment method
US5547676Oct 13, 1993Aug 20, 1996Daniel JouvanceCosmetic product having a stabilized redox potential
US5550183Mar 7, 1995Aug 27, 1996Procyte CorporationMetal-peptide compositions and methods for stimulating hair growth
US5552147Apr 25, 1995Sep 3, 1996Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.Petroleum jelly with alpha hydroxy carboxylic acids
US5554375Jan 6, 1995Sep 10, 1996Skin Biology, Inc.Tissue protective and regenerative compositions
US5554647Apr 27, 1995Sep 10, 1996Perricone; Nicholas V.Method and compositions for treatment and/or prevention of skin damage and aging
US5582817Feb 3, 1993Dec 10, 1996Otsuka Pharmaceutical Co., Ltd.Remedy for dermatopathy and metallothionein inducer
US5597550Dec 9, 1994Jan 28, 1997Buxing MoApparatus and method for administering minerals
US5597552Dec 14, 1993Jan 28, 1997Block Drug Company Inc.Dentinal desensitizing compositions
US5616313Apr 11, 1995Apr 1, 1997Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.Method for treating gingival and periodontal tissues
US5622724Aug 26, 1993Apr 22, 1997Kappa Pharmaceuticals LimitedSpray preparation for treating symptoms of the common cold containing unchelated ionic zinc compounds
US5624675Nov 12, 1993Apr 29, 1997Kelly; Patrick D.Genital lubricants containing zinc salts to reduce risk of HIV infection
US5631013Aug 7, 1995May 20, 1997Church & Dwight Co., Inc.Cosmetic deodorant products containing encapsulated co-micronized bicarbonate ingredient
US5632972Jun 30, 1994May 27, 1997Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.Method for treating gingival and periodontal tissues
US5645840Oct 12, 1995Jul 8, 1997Church & Dwight Co., Inc.Ultrafine sodium bicarbonate powder
US5663213Aug 24, 1995Sep 2, 1997Rohm And Haas CompanyMethod of improving ultraviolet radiation absorption of a composition
US5686083Aug 11, 1995Nov 11, 1997Schering-Plough Healthcare Products Inc.Compositions for treating corns and calluses
US5688492Jul 22, 1996Nov 18, 1997The Boots Company Plc,Oral hygiene composition
US5690967Jun 7, 1995Nov 25, 1997Tristrata Technology, Inc.Compositions for improved topical delivery of lactic acid
US5696169Mar 7, 1994Dec 9, 1997Otsuka Pharmaceutical Co., Ltd.Antibacterial and antifungal activity method, therapeutic method of infectious diseases and preserving method of cosmetics
US5698184Aug 23, 1996Dec 16, 1997Skin Biology, Inc.Compositions and methods for skin tanning and protection
US5707609Dec 27, 1996Jan 13, 1998Mo; BuxingApparatus and method for administering minerals
US5708023Mar 28, 1995Jan 13, 1998The Trustees Of Columbia University In The City Of New YorkZinc gluconate gel compositions
US5728404Feb 17, 1993Mar 17, 1998Henkel Kommanditgesellschaft Auf AktienVirucidal disinfectant
US5747005Aug 2, 1995May 5, 1998Barels; Ronald R.Oil-based, anti-plaque dentifrice composition
US5753637Jan 8, 1997May 19, 1998Ideal Ideas, Inc.Method of treating acne conditions
US5762945Apr 5, 1996Jun 9, 1998Ashley; ElineComposition and method for treating diaper rash
US5780020Oct 28, 1996Jul 14, 1998The Proctor & Gamble CompanyMethods and compositions for reducing body odor
US5795574Sep 9, 1996Aug 18, 1998Societe L'oreal S.A.Use of an extract from a non-photosynthetic filamentous bacterium and composition containing it
US5798121Dec 19, 1995Aug 25, 1998L'orealStable cosmetic, dermatological or pharmaceutical composition comprising selenium disulphide and at least one zinc salt
US5827884Jun 28, 1996Oct 27, 1998Omp Acquisition CorporationSkin peel maintenance composition and method
US5837270Aug 26, 1996Nov 17, 1998Burgess; Nelson LeonTopical anti-acne composition
US5855873Oct 27, 1997Jan 5, 1999Church Dwight & Co., Inc.Stable solution of zinc and bicarbonate ions
US5858335Jun 9, 1997Jan 12, 1999The Procter & Gamble CompanyMethod of reducing body odor using perfume-free two phase compositions
US5858371Apr 21, 1997Jan 12, 1999Panacea Biotech LimitedPharmaceutical composition for the control and treatment of anorectal and colonic diseases
US5858993Sep 13, 1996Jan 12, 1999Skin Biology, Inc.Starch-metal complexes for skin and hair
US5861143Jun 9, 1997Jan 19, 1999The Procter & Gamble CompanyMethods for reducing body odors and excess moisture
US5861144Jun 9, 1997Jan 19, 1999The Procter & Gamble CompanyPerfumed compositions for reducing body odors and excess moisture
US5861145Jun 9, 1997Jan 19, 1999The Procter & Gamble CompanyMethod of reducing body odor using perfumed, odor absorbing, two phase compositions
US5861146Jun 9, 1997Jan 19, 1999The Procter & Gamble CompanyMethod for reducing body odor
US5861147Jun 9, 1997Jan 19, 1999The Procter & Gamble CompanyMethods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume
US5871718Jun 9, 1997Feb 16, 1999The Procter & Gamble CompanyPerfumed two phase compositions for reducing body odor
US5871719Jun 9, 1997Feb 16, 1999The Procter & Gamble CompanyPerfume-free two phase compositions for reducing body odor
US5874067Oct 15, 1997Feb 23, 1999The Procter & Gamble CompanyMethods for controlling environmental odors on the body
US5874070Jun 9, 1997Feb 23, 1999The Procter & Gamble CompanyCompositions for reducing body odor
US5879666Oct 8, 1997Mar 9, 1999The Procter & Gamble CompanyMethods and compositions for reducing body odor
US5882638Oct 15, 1997Mar 16, 1999The Proctor & Gamble CompanyMethods using uncomplexed cyclodextrin solutions for controlling environmental odors
US5886184Mar 26, 1997Mar 23, 1999Merck & Co., Inc.Finasteride processes
US5888515Dec 11, 1997Mar 30, 1999Albros, L.P.Rhus dermatitis treatment composition and method
US5888522Aug 22, 1997Mar 30, 1999Skin Biology, Inc.Tissue protective and regenerative compositions
US5897854Jun 9, 1997Apr 27, 1999The Procter & Gamble CompanyMethods for reducing body odor
US5897855Oct 8, 1997Apr 27, 1999The Procter & Gamble CompanyMethods and compositions for reducing body odor
US5897856Oct 8, 1997Apr 27, 1999The Procter & Gamble CompanyMethods and compositions for reducing body odor
US5904921 *Jan 22, 1997May 18, 1999ColeticaStabilized compositions of superoxide dismutase obtained from germinated plant seeds
US5911976Oct 8, 1997Jun 15, 1999The Procter & Gamble CompanyCompositions for reducing body odor
US5928631Jun 9, 1997Jul 27, 1999The Procter & Gamble CompanyMethods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US5928658Dec 5, 1997Jul 27, 1999U.S. CosmeticsOil-free wax-free solid cosmetic composition
US5928659Feb 26, 1998Jul 27, 1999Moy; Lawrence S.Cosmetic formulation and method for amelioration of skin keratoses and striae distensae
US5935608Apr 15, 1997Aug 10, 1999Nittetsu Mining Co., Ltd.Antibacterial titania and process for producing the same
US5942214Jun 9, 1997Aug 24, 1999The Procter & Gamble CompanyMethods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume
US5948390Aug 18, 1998Sep 7, 1999Pfizer Inc.Stable zinc/citrate/CPC oral rinse formulations
US5951990May 9, 1997Sep 14, 1999Avon Products, Inc.Ascorbyl-phosphoryl-cholesterol
US5955067Jul 23, 1996Sep 21, 1999Oge; ErayPotassium-containing composition useful in the treatment of acne, psoriasis and seborrhea
US5961993Aug 15, 1997Oct 5, 1999L'orealComposition containing a non-photocatalytic metal oxide and tocopherol, its use in the treatment of acne
US5965137Nov 16, 1998Oct 12, 1999Advanced Medical InstrumentsInsect repellent composition and method for inhibiting the transmission and treatment of symptoms of vector-borne diseases
US5965610Jun 9, 1997Oct 12, 1999The Trustees Of Columbia University In The City Of New YorkComposition for inactivating irritants in fluids
US5972999Sep 3, 1998Oct 26, 1999Murad; HowardPharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5980477 *Jul 25, 1998Nov 9, 1999Patrick KellyGenital lubricants with zinc salts as anti-viral additives
US5994403Dec 17, 1997Nov 30, 1999Donatiello; Steven T.Tannin (tannic acid) treatment of athlete's foot and other fungal infections
US6019976Mar 25, 1998Feb 1, 2000Bryant; Andrew EdwardFormulations for treating male pattern baldness containing Serenoa repens, Vitamin B6, Vitamin B3, zinc and L-Arginine
US6022565Mar 26, 1999Feb 8, 2000Albros, L.P.Rhus dermatitis treatment composition and method
US6030605Jan 8, 1999Feb 29, 2000Nabisco, Inc.Breath freshening compositions and methods using them
US6037386Aug 31, 1999Mar 14, 2000The Trustees Of Columbia University In The City Of New YorkComposition for inactivating irritants in fluids
US6046178Apr 18, 1997Apr 4, 2000Deroyal Industries, Inc.Method and compound for treating wounds with starch hydrolysate medication
US6060079Sep 9, 1998May 9, 2000Freeman; FrankDevice for topical localized administration of zinc to tissue
US6071543Jun 1, 1998Jun 6, 2000Cellegy Pharmaceuticals, Inc.Pyridine-thiols reverse mucocutaneous aging
US6083490Nov 6, 1996Jul 4, 2000M&J Consultants Pty LtdUV absorbing compositions
US6086666Jul 2, 1998Jul 11, 2000Merck Patent Gesellschaft Mit Beschrankter HaftungPigment for shielding of ultraviolet radiation
US6103247May 1, 1998Aug 15, 2000L'orealComposition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetics and/or dermatological field and processes employing it
US6103273Jun 21, 1994Aug 15, 2000Antoun; JacquesPharmaceutical composition comprising starch, a compound comprising boron, a compound comprising zinc, and water, and a method of using same to encourage hair growth
US6113636Nov 20, 1997Sep 5, 2000St. Jude Medical, Inc.Medical article with adhered antimicrobial metal
US6121254Mar 17, 1999Sep 19, 2000Societe L'oreal S.A.Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith
US6123925Jul 27, 1998Sep 26, 2000Healthshield Technologies L.L.C.Antibiotic toothpaste
US6132743Oct 23, 1997Oct 17, 2000Kanebo, Ltd.Zinc oxide powder with suppressed activity and cosmetic preparation
US6143318Feb 6, 1996Nov 7, 2000Giltech LimitedAntimicrobial composition composed of controlled release glasses
US6149947Oct 8, 1997Nov 21, 2000Greystone Medical Group, Inc.Compositions of oak bark extract related synthetic compositions and method of using same
US6183785Nov 12, 1998Feb 6, 2001Geoffrey J. WestfallTeat disinfectant
US6190407Dec 31, 1998Feb 20, 2001St. Jude Medical, Inc.Medical article with adhered antimicrobial metal
US6191167Feb 23, 1999Feb 20, 2001Tristrata Technology, Inc.Pharmaceutical compositions containing hydroxycarboxylic acid and/or ketocarboxylic acids and methods of using the same
US6200580Sep 9, 1998Mar 13, 2001Miyoshi Kasei, Inc.Powdered base material treated with organic silicon compounds and their method for producing
US6200680Jun 6, 1995Mar 13, 2001Nippon Shokubai Co., Ltd.Fine zinc oxide particles, process for producing the same, and use thereof
US6217914Jul 19, 1999Apr 17, 2001Bioderm, Inc.Ascorbic acid composition and method for treatment of aging or damaged skin
US6221403Aug 5, 1993Apr 24, 2001Seton Healthcare Group PlcTopical composition
US6224896Jul 24, 1998May 1, 2001Curlor Healthcare Technologies, LlcComposition and process for the treatment of epidermal traumas such as decubitus ulcers
US6248370Jul 20, 1998Jun 19, 2001Leroy HarrisSkin treatment and methods
US6261574Feb 9, 1999Jul 17, 2001Jeremiah CostelloCream formulation for topical application
US6267782Aug 31, 1998Jul 31, 2001St. Jude Medical, Inc.Medical article with adhered antimicrobial metal
US6287541Sep 23, 1999Sep 11, 2001Chesebrough-Pond's Usa Co., Divison Of Conopco, Inc.Oral care compositions
US6303651Sep 23, 1999Oct 16, 2001Thione International, Inc.Synergistic antioxidant veterinary compositions
US6322588Aug 17, 1999Nov 27, 2001St. Jude Medical, Inc.Medical devices with metal/polymer composites
US6322820May 22, 2000Nov 27, 2001Sylvain SimoneauComposition of matter and method for the relief of hemorrhoidal conditions
US6331567Jun 12, 1998Dec 18, 2001Mars Uk LimitedEdible composition containing zinc and linoleic acid
US6361800Apr 13, 2000Mar 26, 2002Cooper Concepts, Inc.Multi-vitamin and mineral supplement
US6375942Aug 31, 2000Apr 23, 2002Michael C. RicoSkin healing ointment
US6395301Dec 30, 1999May 28, 2002L'oréalAnhydrous hydrophobic cosmetic composition in the form of a compact powder
US6416744Jun 21, 2001Jul 9, 2002Colgate Palmolive CompanyTooth whitening chewing gum
US6444699Dec 7, 2000Sep 3, 2002Bioderm, Inc.Method for treatment of aging or damage skin
US6451294Apr 12, 1999Sep 17, 2002L'orealMethod and makeup kit containing goniochromatic and monochromatic pigments
US6471972May 28, 1999Oct 29, 2002Lvmh RechercheCosmetic treatment method for fighting against skin ageing effects
US6475526Jun 5, 2001Nov 5, 2002Jeffrey B. SmithZinc containing compositions for anti-viral use
US6517849Sep 12, 2000Feb 11, 2003The Procter & Gamble CompanyTissue products containing antiviral agents which are mild to the skin
US6521265Jun 13, 2000Feb 18, 2003Biolife, L.L.C.Method for applying a blood clotting agent
US6558710Jun 14, 1999May 6, 2003Helen Rebecca GodfreyTopical zinc compositions and methods of use
US6579541Mar 16, 2001Jun 17, 2003Marantech Holding, LlcOxidative fluorinator compounds as antimicrobials
US6582684Mar 21, 2000Jun 24, 2003Xsight InternationalBody coating composition
US6582710Jan 29, 2002Jun 24, 2003Sembiosys Genetics Inc.Products for topical applications comprising oil bodies
US6592852Apr 25, 2002Jul 15, 2003Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Zinc citrate beads in oral compositions
US6599513Oct 24, 2001Jul 29, 2003Sembiosys Genetics Inc.Products for topical applications comprising oil bodies
US6607716Mar 26, 2001Aug 19, 2003Tech Labs, Inc.Pediculicidal compositions, a kit, and methods of use
US6627178Jul 30, 1999Sep 30, 2003Garret D. CawthonMethods, compositions and systems for the prevention and treatment of diaper rash
US6660306Apr 18, 2002Dec 9, 2003Mickey L. PeshoffWound healing compound
US6663852Aug 15, 2002Dec 16, 2003L'orealMethod and makeup kit containing goniochromatic and monochromatic pigments
US6680073Apr 10, 2000Jan 20, 2004Bryon J. TarbetComposition and method for the treatment of onychomycosis in animals
US6682720Dec 27, 2002Jan 27, 2004Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Zinc citrate beads in oral compositions
US6696071Nov 27, 2001Feb 24, 2004Patrick D. KellyPre-coital and post-coital rinse with anti-viral and skin-protective zinc salts
US6726919Jun 14, 2001Apr 27, 2004Rtp Pharma, Inc.Injectable dispersion of propofol
US6730309Jul 2, 2001May 4, 2004Miyoshi Kasei, Inc.Sebum-adsorbent powder and use thereof
US6730329Feb 26, 2002May 4, 2004Jeffrey B. SmithZinc containing compositions for anti-viral use
US6743416Sep 30, 2002Jun 1, 2004Bonnie RiedlSunscreen for animals
US6750209Mar 8, 2000Jun 15, 2004Kansas University Medical CenterAdvanced glycation end-product intermediaries and post-amadori inhibition
US6773698Jun 9, 2003Aug 10, 2004Silvia MelinteTattoo removal
US6780439Mar 6, 2001Aug 24, 2004J. Ronald WilkWound treatment solution and method for using same
US6800301Apr 9, 2001Oct 5, 2004Sadie N. SmithMulti-purpose skin balm including skin balm for psoriasis
US6833362Jun 7, 2001Dec 21, 2004Ward Beryl Bowen, Jr.Method and composition for the accelerated in vivo removal of ethanol
US6844012Aug 30, 1999Jan 18, 2005Xavier ForcevilleUse of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing said treatment
US6849277Aug 8, 2002Feb 1, 2005Juan Carlos RoigComposition for moist skin
US6855341Nov 4, 2002Feb 15, 2005Jeffrey B. SmithAnti-viral compositions and methods of making and using the anti-viral compositions
US6858201Feb 15, 2002Feb 22, 2005Skin Biology, Inc.Methods for treating fingernails and toenails
US6929800Aug 6, 2001Aug 16, 2005Abdul Rasoul SalmanNasal passage cleaning composition
US6932976Aug 8, 2002Aug 23, 2005Kimberly-Clark Worldwide, Inc.Enzyme blocking skin protectant cream
US6939568Apr 23, 2002Sep 6, 2005Nucryst Pharmaceuticals Corp.Treatment of inflammatory skin conditions
US6942878Sep 10, 2001Sep 13, 2005Showa Denko K.K.Cosmetic composition
US6949248Sep 25, 2001Sep 27, 2005Shiseido Co., Ltd.Metal oxide/silica composite, and a cosmetic preparation comprising thereof
US6949249Apr 30, 2001Sep 27, 2005Pfizer Inc.Skin protectant spray compositions
US6964782Jul 7, 2003Nov 15, 2005Tec Labs, Inc.Stable hydrogen peroxide compositions, products and methods of use
US6989156Apr 23, 2002Jan 24, 2006Nucryst Pharmaceuticals Corp.Therapeutic treatments using the direct application of antimicrobial metal compositions
US7008647Apr 23, 2001Mar 7, 2006Nucryst Pharmaceuticals Corp.Treatment of acne
US7014870Nov 20, 2000Mar 21, 2006Greystone Medical Group, Inc.Compositions of oak bark extract related synthetic compositions and method of using same
US7026308 *Jun 22, 2000Apr 11, 2006The Procter & Gamble CompanyTopical anti-microbial compositions
US7049339Jun 14, 2002May 23, 2006Forty Eight Shelf (80) LimitedComposition for the treatment of diseases which affect animals' hooves
US20010014356Dec 21, 2000Aug 16, 2001Yuzo YoshidaPlasminogen activator inhibitor and external preparation for skin comprising the same
US20010041193Dec 7, 2000Nov 15, 2001Bioderm, Inc.Method for treatment of aging or damaged skin
US20020001629Aug 24, 2001Jan 3, 2002Voellmy Richard W.Compositions and methods relating to prevention of chemotherapy-induced alopecia
US20020031557Nov 21, 2001Mar 14, 2002Meisner Lorraine FaxonAscorbic acid composition and method for treatment of aging or damaged skin
US20020114847Apr 18, 2002Aug 22, 2002Peshoff Mickey L.Wound healing compound
US20020182244May 31, 2002Dec 5, 2002Jackson Sherry D.Dietary supplements
US20030004564Mar 11, 2002Jan 2, 2003Elkins Christopher J.Drug delivery platform
US20030026848Jul 6, 2001Feb 6, 2003Joshi Ashok V.Beneficial materials for topical or internal use by a human or other animal
US20030035825Aug 1, 2001Feb 20, 2003Yen-Kuen ShiauTherapeutic pad and a method for treatment of common illnesses
US20030059484Sep 17, 2002Mar 27, 2003Lvmh RechercheCosmetic treatment method for fighting against skin ageing effects
US20030068351Aug 8, 2002Apr 10, 2003Roig Juan CarlosComposition for moist skin
US20030069369Oct 9, 2002Apr 10, 2003Belenkaya Bronislava G.Biodegradable absorbents and methods of preparation
US20030072819May 6, 2002Apr 17, 2003Yuanjin TaoCompositions and methods for enhancing drug delivery
US20030077304Nov 12, 2002Apr 24, 2003Mccadden Michael E.Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis
US20030077332Dec 2, 2002Apr 24, 2003Allterra, Inc.Topical zinc compositions and methods of use
US20030082219May 21, 2002May 1, 2003The Procter & Gamble CompanySkin care compositions comprising low concentrations of skin treatment agents
US20030082223Apr 30, 2001May 1, 2003Healy Michael SeanSkin protectant spray compositions
US20030099721Jul 25, 2002May 29, 2003Shiseido Co., Ltd.Method for improving morbid dermatitis by inhibiting activity of a plasminogen activator in the skin
US20030118623Dec 16, 2002Jun 26, 2003Gianfranco De Paoli AmbrosiComposition based on etyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhea and acne
US20030133991Nov 27, 2002Jul 17, 2003Greystone Medical Group, Inc.Treatment of wounds and compositions employed
US20030138497Sep 26, 2002Jul 24, 2003Shiseido Co., Ltd.Inorganic antibacterial/antifungal agents
US20030161892Feb 27, 2002Aug 28, 2003Mcfarland Connie L.Topical clotting ointment and method
US20030166510 *Oct 11, 2001Sep 4, 2003Pickart Loren R.Methods and compositions for increasing skin remodeling
US20030190371Oct 15, 2002Oct 9, 2003The Boots Company PlcAntimicrobial agent
US20030194446Apr 10, 2002Oct 16, 2003Akes Lindy K.Zinc oxide compositions for dermatheraputics
US20030199488Apr 22, 2003Oct 23, 2003Trotta Gina M.Treatment of hyperproliferative disorders/inflammatory dermatoses
US20030215412Feb 21, 2003Nov 20, 2003Essentia Biosystems, Inc.Induction of hair growth with vascular endothelial growth factor
US20030215522Mar 18, 2003Nov 20, 2003The Procter & Gamble CompanyPersonal care compositions comprising a zinc containing material in an aqueous surfactant composition
US20030224023Jan 21, 2003Dec 4, 2003Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Cosmetic compositions with hydroxy amine salts of malonic acid
US20030224027Feb 26, 2003Dec 4, 2003Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Cosmetic compositions with ammonium malonates
US20040022863Jul 31, 2002Feb 5, 2004Hamtini Samir I.Topical medicament for treating nappy rash
US20040028708Aug 8, 2002Feb 12, 2004Brooks JoannEnzyme blocking skin protectant cream
US20040033270Jun 17, 2003Feb 19, 2004Christian KropfNano-sized zinc oxide in hygiene products
US20040037910Aug 21, 2003Feb 26, 2004Hon David N. S.Compositions of oak bark extract, related syntheic compositions and method of using same
US20040058011Sep 10, 2003Mar 25, 2004Petersson Lennart G.Powder teat dip germicide, fungicide and skin conditioner
US20040058015Mar 24, 2003Mar 25, 2004Yuanjin TaoCompositions and methods for treating eye discomfort and eye disease
US20040062730Sep 29, 2003Apr 1, 2004Shiseido Co., Ltd.External skin preparation
US20040062817Sep 30, 2003Apr 1, 2004Peshoff Mickey L.Wound healing compound
US20040076686Jan 9, 2002Apr 22, 2004Thomas RiesingerTreatment solution used for caring wounds in addition to dressing material for use with said treatment solution
US20040091551Nov 13, 2002May 13, 2004Al-Karim DamjiTopical composition and application system
US20040101541Nov 27, 2002May 27, 2004Heffernan Michael ScullyElectrolytic cream
US20040109902Nov 28, 2001Jun 10, 2004Mcdonagh Emma LouiseDermatological formulations
US20040131700Oct 22, 2003Jul 8, 2004Essentia Biosystems, Inc.Implantable medical devices using zinc
US20040156875May 7, 2002Aug 12, 2004Pierre FabreCosmetic composition based on zinc and cooper sulphates and sucralphate
US20040157921Oct 22, 2003Aug 12, 2004Essentia Biosystems, Inc.Modulation of zinc levels to improve tissue properties
US20040170701Apr 4, 2002Sep 2, 2004John CarterPharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection
US20040170703Dec 23, 2003Sep 2, 2004Greystone Medical Group, Inc.Reduction of reactive oxygen species in chronic wound management
US20040170712Mar 4, 2004Sep 2, 2004Egyptian Natural OilMedical effect of Jojoba Oil in the treatment of skin diseases
US20040175433Jun 14, 2002Sep 9, 2004William ThomsonComposition for the treatment of diseases which affect animals' hooves
US20040185015Jun 23, 2003Sep 23, 2004Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Sunscreen cosmetic compositions storage stabilized with malonate salts
US20040185074Jun 23, 2003Sep 23, 2004Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Odor control in amine salt containing cosmetic compositions
US20040202689Jan 29, 2004Oct 14, 2004Unilever Home & Personal Care Usa, Division Of Conopco, Inc.Terpenoid fragrance components stabilized with malonic acid salts
US20040220100Mar 3, 2004Nov 4, 2004Essentia Biosystems, Inc.Multi-component biological transport systems
US20040253321Aug 17, 2002Dec 16, 2004Fechner Jorg HinrichAntimicrobial, anti-inflammatory, wound-healing glass powder and use thereof
US20040258769Jun 18, 2004Dec 23, 2004Barker Ronnie C.Use of ocular vitamins in conjunction with other treatment methods for AMD
US20050048010Jun 21, 2004Mar 3, 2005Rainer KlissSurface-modified zinc oxide for the production of nanoparticulate dispersions
US20050069506Mar 10, 2003Mar 31, 2005Degussa AgNanoscale zinc oxide, process for its production and use
US20050069588Mar 4, 2002Mar 31, 2005Leendert TaalPreparation containing polydimethylsiloxane for nail, cartilage,bone, joint,muscle and tendon disorders
US20050074425Jul 2, 2004Apr 7, 2005Polycord, Inc.Method for delivering polymerized therapeutic agent compositions and compositions thereof
US20050079229Jul 24, 2003Apr 14, 2005Cawthon Garret D.Methods, compositions and systems for the prevention and treatment of diaper rash
US20050100571Nov 9, 2004May 12, 2005Larry KeyesMethod and device to treat skin affected by a corn
US20050123620Dec 4, 2003Jun 9, 2005Chiou Consulting, Inc.Compositions and methods for topical treatment of skin infection
US20050136129Nov 22, 2004Jun 23, 2005N. V. NutriciaNutritional composition for the treatment of pressure ulcers
US20050175719Feb 5, 2004Aug 11, 2005Ying SunProcyanidins for treatment and prevention of enzymatic irritation to the skin
US20050202054Mar 15, 2004Sep 15, 2005Faryniarz Joseph R.Methods and compositions useful to prevent in-grown hair arising from shaving
US20050234239Jun 2, 2003Oct 20, 2005Marc TailleferMethod of forming a carbon-carbon or carbon-heteroatom linkage
US20050238730Nov 11, 2002Oct 27, 2005Agnes Le FurCompositions comprising an ethanolamine derivative and organic metal salts
US20060029682Mar 15, 2005Feb 9, 2006Greystone Medical Group, Inc.Treatment of wounds and compositions employed
US20060036007Apr 25, 2005Feb 16, 2006King Industries, Inc.Organometallic compositions and coating compositions
US20060089407Oct 25, 2005Apr 27, 2006National Research Laboratories, Ltd.Methods for Making and Using Synergistic Multifunctional Compositions
US20070032751Aug 3, 2005Feb 8, 2007Sea And Land Therapies, LlcFilled full shell massage implement
USRE33512Dec 23, 1988Jan 1, 1991Chesebrough-Pond's, Inc.Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt
JP2001039809A * Title not available
WO1994014408A1 *Dec 17, 1993Jul 7, 1994Unilever PlcDeodorant composition
WO2004039238A2Oct 22, 2003May 13, 2004Essentia Biosystems IncModulation of zinc levels to improve tissue properties
WO2004039238A3Oct 22, 2003Aug 12, 2004Essentia Biosystems IncModulation of zinc levels to improve tissue properties
Non-Patent Citations
Reference
1Delgado, F., "Alkali-Templated Malonate Copper (II) Complexes", Acta Cryst. A61, C358 (2005).
2Filippova I.G., "Polymorphism of Coordination Compounds with Malonic Ańid", Moldavian Journal of the Physical Sciences, 1vol. 1, No. 3, 87-93 (2002).
3Hernández-Molina M., "A phase transition in the novel three-dimensional compound [Eu2(mal)2(H2O)6] (H2mal=malonic acid)", J.Chem.Soc., Dalton Trans. 2002, vol. 18, 3462.
4Homsy, R. et al., "Characterization of Human Skin Fibroblasts Elastase Activity", J. Invest. Dermatol, vol. 91, 472-477 (1988).
5Naumov, P, et al., "The Crystal Structure of Copper (II) Malonate Trihydrate", CCACAA, vol. 75, No. 3, 701-711 (2002).
6Philip, B., et al., "Dietary Zinc & Levels of Collagen, Elastin & Carbohydrate Components of Glycoproteins of Aorta, Skin & Cartilage in Rats", Indian J. Exp. Biol., vol. 16, 370-372 (1978).
7Rodríguez-Martín Y., "Alternating cationic-anionic layers in the [MlI(H2O)6][CuII(mal)2(H2O)] complexes linked through hydrogen bonds (M=Mn, Co, Ni, Cu and Zn; H2mal=Malonic acid)", CrystEngComm, 2002, vol. 4, No. 107, 631.
8Rodríguez-Martín, Y., "Extended network via hydrogen bond linkages of coordination compounds: Synthesis, crystal structure and thermal behavior of the complexes [MII(L)2(NO3)2] (MII=Cu, Co) and [Ni(L)2(H2O)].(NO3)2 (L=malonamide)", Inorganica Chimica Acta. vol. 328, 169-178 (2002).
9Rodríguez-Martín, Y., "Extended network via hydrogen bond linkages of coordination compounds: Synthesis, crystal structure and thermal behavior of the complexes [MII(L)2(NO3)2] (MII=Cu, Co) and [Ni(L)2(H2O)]•(NO3)2 (L=malonamide)", Inorganica Chimica Acta. vol. 328, 169-178 (2002).
10Rodríguez-Martín, Y., "Structural Versatility of the Malonate Ligand as a Tool for Crystal Engineering in the Design of Molecular Magnets", Cryst. Eng. Comm. 2002, vol. 4, No. 87, 522-535.
11Rodríguez-Martín, Y., "Synthesis, crystal structure and magnetic properties of [Cu(bpym)(mal)(H2O)].6H2O and [Cu2(bpym)(mal)2(H2O)2].4H2O (bpym=2,2'-bipyrimidine, H2mal=Malonic Acid)", Inorganica Chimica Acta. vol. 326, 20-26 (2001).
12Rodríguez-Martín, Y., "Synthesis, crystal structure and magnetic properties of [Cu(bpym)(mal)(H2O)]•6H2O and [Cu2(bpym)(mal)2(H2O)2]•4H2O (bpym=2,2′-bipyrimidine, H2mal=Malonic Acid)", Inorganica Chimica Acta. vol. 326, 20-26 (2001).
13Rodríguez-Martín, Y., "The flexibility of molecular components as a suitable tool in designing extended magnetic systems", Cryst. Eng. Comm. 2002, vol. 4, No. 73, 440-446.
14Ruiz-Pérez, C., "Dimensionally controlled hydrogen-bonded nanostructures: Synthesis, structure, thermal and magnetic behaviour of the tris-(chelated)nickel(II) complex [Ni(bipy)3]Cl2.5.5H2O (bipy=2,2′-bipyridine)", Inorg. Chim. Acta. 2002, vol. 336, 131-136.
15Ruiz-Pérez, C., "Dimensionally controlled hydrogen-bonded nanostructures: Synthesis, structure, thermal and magnetic behaviour of the tris-(chelated)nickel(II) complex [Ni(bipy)3]Cl2.5.5H2O (bipy=2,2'-bipyridine)", Inorg. Chim. Acta. 2002, vol. 336, 131-136.
16Sanchiz, J., "Ferromagnetic coupling in the malonato-bridged copper(II) chains {[Cu(Im)2(mal)]}n and {[Cu(2-MeIm)2(mal)]}n (H2mal=Malonic Acid, Im=imidazole and 2-MeIm=2-methylimidazole)", New J. Chem. 2002, vol. 26, 1624.
17Tinker, D. et al., "Role of Selected Nutrients in Synthesis, Accumulation, and Chemical Modification of Connective Tissue Proteins", Physiolgical Reviews, vol. 65, No. 3, 607-657 (1985).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US20120177747 *Jan 9, 2012Jul 12, 2012Noble Ion, LlcCompositions and Methods for Treating Lameness in Hoofed Domesticated Animals Due to Hairy Foot Warts and Foot Rot
Classifications
U.S. Classification424/401, 424/69, 424/617, 424/642, 424/400, 424/630, 424/641, 424/67
International ClassificationA61K33/34, A61K8/02, A61K33/30
Cooperative ClassificationA61K8/361, A61K8/27, A61Q19/08, A61K31/19, A61K8/365, A61K45/06, A61K8/362, A61K31/315, A61K8/19, A61K31/765, A61K8/44, A61K31/30, A61K33/34, A61K33/30, A61K9/0014
European ClassificationA61K31/765, A61K33/30, A61K31/315, A61K8/36C, A61Q19/08, A61K8/362, A61K8/19, A61K8/27, A61K8/44, A61K31/19, A61K8/365, A61K33/34, A61K45/06, A61K31/30
Legal Events
DateCodeEventDescription
Sep 21, 2006ASAssignment
Owner name: JR CHEM, LLC, FLORIDA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FARYNIARZ, JOSEPH R.;RAMIREZ, JOSE E.;REEL/FRAME:018308/0391
Effective date: 20060808
Jan 24, 2014ASAssignment
Effective date: 20131101
Owner name: OBAGI MEDICAL PRODUCTS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JR CHEM, LLC;REEL/FRAME:032040/0855
Sep 25, 2014FPAYFee payment
Year of fee payment: 4